I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Luzindole significantly antagonizes melatonin-mediated antinociception, suggesting that MEL-1B-R plays a further role as a mediator of melatonin modulation of pain signaling. It is used both in vitro and in vivo to evaluate the roles of melatonin receptor signaling in diverse pathways, including circadian rhythms, animal behavior, and melanophore response
C Browning; I Beresford; N Fraser, H Giles. Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. British Journal of Pharmacology. 2000, 129, (5), 877-886.
M L Dubocovich. Luzindole (N-0774): a novel melatonin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics. 1988, 246, (3), 902-910.